Brought to you by 
Denali gets Genentech's LRRK2 inhibitors for Parkinson's disease
26 Aug 2016
Executive Summary
Among several deals announced on the same day, Denali Therapeutics Inc. received an exclusive worldwide license to develop and sell Roche's Genentech Inc.'s leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson's disease.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Denali gets Genentech's LRRK2 inhibitors for Parkinson's disease
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice